AIDAN KING is listed as a director on 2 SEC Form D filings by 2 issuers between Sep 2016 and Oct 2026: CHRONO THERAPEUTICS INC. (Hayward, CA — other health care — 2016; $37.6M reported sold to 31 investors) and Altay Therapeutics, Inc. (San Carlos, CA — biotechnology — 2026; $15.7M reported sold to 19 investors).
What this means 2 separate companies raised money with this person listed as director, over about 10 years. Across those companies the filings report $53.3M sold in total.
Listed alongside ALI OZES (1 shared filing), Alan Levy, Ph.D. (1 shared filing), Anthony Rimac (1 shared filing), CHELSEA JOHNSON (1 shared filing), ELIZABETH ROCKETT (1 shared filing) and 9 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around AIDAN. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 2 public filings for AIDAN KING and found 3 differences: No amendment in the last 12 months on an offering that may still be open; Same name, different state: "Aidan King" (L2 or MA or PA) is a separate record; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.